

# Epalrestat

Catalog No: tcsc2417



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

82159-09-9

**Formula:**

$C_{15}H_{13}NO_3S_2$

**Pathway:**

Metabolic Enzyme/Protease

**Target:**

Aldose Reductase

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 3.2$  mg/mL (10.02 mM)

**Alternative Names:**

ONO2235

**Observed Molecular Weight:**


319.4

## Product Description

Epalrestat is an aldose reductase inhibitor for the treatment of diabetic neuropathy.

Target: Aldose Reductase

Epalrestat may affect or delay progression of the underlying disease process. Data from six clinical trials were evaluated, and it was determined that epalrestat 50 mg 3 times/day may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms as compared with baseline and placebo. Epalrestat may serve as a new therapeutic option to prevent or slow the progression of diabetic neuropathy [1]. Epalrestat significantly increased the amplitude of 3 cpm waves on EGG and improved the spectral analytical parameters of heart rate variability. These findings suggest that epalrestat is useful for the treatment of diabetic gastroparesis [2]. Epalrestat is a highly effective and safe agent for the treatment of diabetic neuropathy [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!